Sanofi (NASDAQ:SNY) Shares Sold by Leisure Capital Management

Leisure Capital Management decreased its holdings in Sanofi (NASDAQ:SNY) by 21.4% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 17,863 shares of the company’s stock after selling 4,868 shares during the quarter. Leisure Capital Management’s holdings in Sanofi were worth $888,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Rise Advisors LLC grew its position in Sanofi by 98.4% in the fourth quarter. Rise Advisors LLC now owns 506 shares of the company’s stock worth $25,000 after buying an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new position in Sanofi in the fourth quarter worth approximately $27,000. Venturi Wealth Management LLC grew its position in Sanofi by 163.5% in the fourth quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock worth $27,000 after buying an additional 332 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA boosted its stake in Sanofi by 115.6% in the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock worth $37,000 after purchasing an additional 400 shares during the period. Finally, CNB Bank acquired a new position in Sanofi in the 3rd quarter worth approximately $39,000. Institutional investors and hedge funds own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on SNY shares. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. TheStreet lowered shares of Sanofi from a “b” rating to a “c” rating in a research note on Friday, February 9th. Finally, Morgan Stanley assumed coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $55.00.

Sanofi Stock Down 0.5 %

Shares of SNY stock traded down $0.23 on Friday, hitting $49.13. The company’s stock had a trading volume of 4,148,180 shares, compared to its average volume of 2,214,580. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $56.26. The firm’s fifty day moving average price is $47.71 and its 200-day moving average price is $48.41. The stock has a market capitalization of $124.28 billion, a price-to-earnings ratio of 24.69, a P/E/G ratio of 1.49 and a beta of 0.61.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, February 1st. The company reported $0.89 EPS for the quarter, missing the consensus estimate of $0.94 by ($0.05). The firm had revenue of $11.76 billion during the quarter, compared to the consensus estimate of $13.02 billion. Sanofi had a return on equity of 19.69% and a net margin of 10.52%. Research analysts anticipate that Sanofi will post 4.09 EPS for the current year.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. This represents a yield of 2.98%. Sanofi’s payout ratio is currently 69.35%.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.